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Background: Hyperglycemia is associated with increased risk of all-site cancer that may be mediated through
activation of the renin-angiotensin-system (RAS) and 3-hydroxy-3-methyl-glutaryl-coenzyme-A-reductase (HMGCR)
pathways. We examined the joint associations of optimal glycemic control (HbA1c <7%), RAS inhibitors and HMGCR
inhibitors on cancer incidence in patients with type 2 diabetes.
Methods: Patients with type 2 diabetes, with or without a history of cancer or prior exposure to RAS or HMGCR inhibitors
at baseline were observed between 1996 and 2005. All patients underwent a comprehensive assessment at baseline and
were followed until the censored date at 2005 or their death.
Results: After a median follow-up period of 4.91 years (interquartile range, 2.81 to 6.98), 271 out of 6,103 patients
developed all-site cancer. At baseline, patients with incident cancers were older, had longer disease duration
of diabetes, higher alcohol and tobacco use, and higher systolic blood pressure and albuminuria, but lower
triglyceride levels and estimated glomerular filtration rate (P <0.05). Patients who developed cancers during
follow-up were less likely to have started using statins (22.5% versus 38.6%, P <0.001), fibrates (5.9% versus 10.2%,
P = 0.02), metformin (63.8% versus 74.5%, P <0.001) or thiazolidinedione (0.7% versus 6.8%, P <0.001) than those
who remained cancer-free. After adjusting for co-variables, new treatment with metformin (hazard ratio: 0.39; 95%
confidence interval: 0.25, 0.61; P <0.001), thiazolidinedione (0.18; 0.04, 0.72; P = 0.015), sulphonylurea (0.44; 0.27,
0.73; P = 0.014), insulin (0.58; 0.38, 0.89; P = 0.01), statins (0.47; 0.31, 0.70; P <0.001) and RAS inhibitors (0.55; 0.39,
0.78; P <0.001) were associated with reduced cancer risk. Patients with all three risk factors of HbA1c ≥7%, non-use of
RAS inhibitors and non-use of statins had four-fold adjusted higher risk of cancer than those without any risk factors
(incidence per 1,000-person-years for no risk factors: 3.40 (0.07, 6.72); one risk factor: 6.34 (4.19, 8.50); two risk factors:
8.40 (6.60, 10.20); three risk factors: 13.08 (9.82, 16.34); P <0.001).
Conclusions: Hyperglycemia may promote cancer growth that can be attenuated by optimal glycemic control and
inhibition of the RAS and HMGCR pathways.
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Diabetes increases the risk of vascular, cancer, non-
vascular and non-cancer deaths by 1.3 to 3-fold com-
pared with non-diabetic subjects [1]. Our group [2] and
others [1] have reported linear associations between gly-
cemia (glycated hemoglobin (HbA1c) and fasting plasma
glucose) and cancer risk in diabetic and non-diabetic
subjects. Experimentally, chronic hyperglycemia can acti-
vate interlinked molecular pathways, resulting in oxidative
stress, inflammation and abnormal cell cycles, which
can be implicated in carcinogenesis [3-5]. In diabetes,
while control of blood lipids, blood pressure, blood
glucose and inhibition of the renin-angiotensin system
(RAS) can reduce cardiovascular and/or renal events,
cancer is emerging as an important co-morbidity, espe-
cially in areas such as Asia with lower prevalence of
coronary heart disease compared to the West [6,7].
The Hong Kong Diabetes Registry was established in
1995, comprising a prospective cohort with documenta-
tion of risk factors, clinical outcomes and drug usage [8,9].
Using this Registry, we have made important observations:
all-site cancer accounted for 25% of diabetes-related
deaths, led by hepatocellular and colorectal cancer; a 1%
increase in HbA1c was associated with an 18% increased
hazard ratio (HR) of all-site cancer after adjustment for
confounders including drug use; use of insulin, sulphony-
lurea, metformin, thiazolidinedione (TZD), RAS inhibitors
or statins was associated with reduced cancer risk; and
there were non-linear risk associations between lipids and
cancer [2].
Based on these findings, we asked whether optimal
glycemic control and the use of statins and RAS inhibi-
tors could reduce risk of cancer in a synergistic manner
due to the interlinking nature of these molecular pathways
(Figure 1). We tested this hypothesis using the Hong Kong
Diabetes Registry comprising a prospective cohort of 6,103
patients with type 2 diabetes without cancer or exposure to
these drugs before enrolment.
Methods
Patients
The Hong Kong Diabetes Registry was established in
1995 as a quality improvement program, with a weekly
enrolment of 30 to 50 ambulatory patients with diabetes
who were referred from community- and hospital-based
clinics. All patients underwent a comprehensive assess-
ment of complications and risk factors and would be
followed until their death. From 1 December 1996 to 9
January 2005, 7,387 patients with diabetes were enrolled
in the Registry. After excluding 323 patients with type 1
diabetes (acute presentation with diabetic ketoacidosis,
heavy ketonuria (urine value classed above 3+) or continu-
ous requirement of insulin within one year of diagnosis), 5
with missing type of diabetes, 45 with non-Chinese orunknown ethnicity, 175 with a history of cancer or receiv-
ing anti-cancer treatment and 736 with missing values in
any of the variables used in the analysis, 6,103 patients
were included in this analysis. The study was approved by
the Chinese University of Hong Kong Clinical Research
Ethics Committee with written informed consent from all
participants.
Baseline assessment and endpoint ascertainment
The assessment method had been described previously
[8,9]. After an 8-hour overnight fast, structured assessment
of the eye, feet, urine and blood was performed on all en-
rolled patients. The eye examination included visual acuity,
fundoscopy through dilated pupils or retinal photography.
A Doppler ultrasound scan, monofilament and graduated
tuning fork were used to examine the foot. Blood samples
were taken for measurement of fasting plasma glucose,
HbA1c, lipid profile (high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C) and
triglyceride) and renal function. A sterile spot urine sample
was used to measure albumin-to-creatinine ratio (ACR).
We used the Chinese-calibrated Modification of Diet in
Renal Disease study formula to estimate glomerular filtra-
tion rate (eGFR), expressed in ml/min/1.73 m2:
eGFR ¼ 186 serum creatinine 0:011½ −1:154
 age½ −0:203  0:742 if female½   1:233;
where serum creatinine is given as micromoles per liter
and 1.233 is the adjusting coefficient. All laboratory
assays were performed at the Department of Chemical
Pathology, the Prince of Wales Hospital, Hong Kong,
China using externally audited assays with precision
within the manufacturers’ specifications.
Hong Kong is a cosmopolitan city of 7 million people
with an ethnic majority of Southern Chinese. It has a
heavily subsidized healthcare system that provides 95%
of acute and chronic care. All public health enterprises
are governed by the Hospital Authority and share a
territory-wide Electronic Patient Record System includ-
ing a death registry, which can be matched to a unique
Hong Kong identity number held by all citizens. The
system accurately captures prescription of all medications
issued by public hospitals and clinics. Details of medication
use, including the start and end dates of use, were retrieved
from the system. We also used the Hospital Authority
electronic system to identify first cancer events, fatal
or non-fatal, using the International Classification of
Diseases, Ninth Revision (code 140–208), censored on
or before 30 July 2005.
Statistical analyses
All analysis was performed using the Statistical Analysis
System (Release 9.10, SAS Institute Inc., Cary, NC, USA).
Figure 1 A schematic diagram summarizing possible mechanisms underlying the risk associations of cancer with diabetes and the
attenuating effects of statins, renin-angiotensin-system inhibitors (angiotensin-converting enzyme inhibitors and angiotensin II
receptor blockers), insulin and oral anti-diabetic drugs on cancer risk. Apart from obesity-associated insulin resistance, which can activate
cell-signaling pathways such as the insulin-like growth factor-1 (IGF1) pathway to increase risk of cancer, hyperglycemia and dyslipidemia due to
insufficient insulin action can activate angiotensin II, inflammatory and redox pathways that share multiple intracellular signals, including sterol
regulatory element-binding proteins (SREBP), 3-hydroxy-3-methyl-glutaryl-CoA-reductase (HMGCR), adenosine monophosphate-activated protein
kinase (AMPK) and nuclear factor kappa B (NF-KB) pathways to cause abnormal cell cycles to increase cancer risk. Treatment with RAS and HMGCR
inhibitors together with correction of hyperglycemia including insulin, insulin sensitizers and insulin secretagogues can block these pathways at
multiple sites to break the vicious cycles. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II blockers; OAD, oral anti-diabetic
drugs.
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propensity scores for RAS inhibitors, statins, insulin,
metformin, sulphonylurea and TZDs, using age, sex,
use of alcohol and tobacco, diabetes duration, body
mass index (BMI), systolic blood pressure (BP), LDL-C,
HDL-C, triglyceride, log values of urinary ACR, eGFR,
retinopathy, neuropathy, peripheral arterial disease, his-
tory of coronary heart disease, and stroke as independent
variables.
We used time-fixed Cox regression models to evaluate
the independent risk associations of cancer with use of
RAS inhibitors, statins and blood glucose-lowering drugs
(insulin, metformin, sulphonylurea, TZD) after excluding
prevalent users and adjustment for propensity score.
Using restricted cubic spline within Cox proportional
hazard regression, we have previously demonstrated non-
linear risk associations of BMI (<24.0 or ≥27.6 kg/m2),
LDL-C, HDL-C and triglyceride with cancer in type 2
diabetes [10-13]. We identified additive interaction be-
tween low LDL-C and albuminuria on cancer risk
[11,13]. We reported positive risk associations of can-
cer with LDL-C <2.8 mmol/L plus albuminuria, and
with LDL-C ≥3.8 mmol/L [10,11,13]. Thus, in the final
Cox model, the association of cancer and the use of spe-
cific drugs was adjusted by the following variables: BMI
(<24.0 or ≥27.6 kg/m2), LDL-C-related risk indicators
(LDL-C <2.8 mmol/L plus albuminuria, or LDL-C ≥3.8
mmol/L), non-linear associations of HDL-C and triglyceridewith cancer, age, sex, occupation, use of alcohol and
tobacco, duration of diabetes, systolic BP, HbA1c, and use
of other drugs during follow-up (oral blood glucose-
lowering drugs, insulin, lipid-lowering drugs and RAS
inhibitors as appropriate). Of note, only cancer events that
occurred after the commencement of the specific drug
were captured in the exposed group. That is, if cancer de-
veloped prior to drug exposure, the event was considered
to occur in the unexposed group. Lastly, we obtained
the adjusted cumulative incidence of cancer stratified by
a combination of attaining optimal glycemic control
(HbA1c <7%) at baseline and commencement of statins
and RAS inhibitors on cancer risk after adjusting
for all co-variables, using time-fixed Cox models (SPSS
version 16, Chicago, IL, USA). Given 271 cancer events
and 20 co-variables, over-fitting of the models was un-
likely (the ratio of the number of endpoints to the
number of co-variables was >10). All data were expressed
as mean ± standard deviation (SD) or median (interquar-
tile range (IQR)), or HR with 95% confidence intervals
(CI). A P-value less than 0.05 (two-tailed) was considered
significant.
Addressing potential biases in pharmacoepidemiological
analysis
In view of the controversies in pharmacoepidemiological
analysis, there is a need to explain potential biases in
analyzing the association of drug use with clinical
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tackle these anticipated biases in this analysis. First,
because the condition associated with drug use may
contribute to the clinical outcome, for which the drug
is prescribed to reduce risk, the propensity score for
use of the drug is used to adjust for the drug indication
[14]. Second, inclusion of existing users of drugs of
interest will introduce prevalent user bias. Here, existing
users at baseline may have an inherent advantage over
non-users, being more likely to survive the initial event
that prompted drug initiation and more tolerant of and/or
better adhered to the drug of interest. Furthermore, alter-
ation of risk profile by the drug in question complicates
statistical adjustment of these risk factors. Exclusion of
prevalent users by including only new users in the analysis
is a common procedure to eliminate prevalent user bias.
Third, and most controversial, is the exposure misclassifi-
cation related to immortal time. Immortal time refers to
the initial period of follow-up among drug users, when the
outcome of interest cannot occur due to the definition of
drug use. To control for immortal time bias, Suissa et al.
[15] and Levesque et al. [16] suggested using either a
time-dependent Cox model or, alternatively, the removal
of the immortal time period from the user cohort in a
time-fixed Cox model. We have previously demonstrated
that using time-dependent drug-exposure Cox models to
estimate the effects of drug use in diabetes results in a
severely inflated HR [4], probably because of a failure
to consider for parallel metabolic worsening in a time-
dependent manner. In this present analysis, we re-
examined the validity of the different statistical procedures
in quantifying drug effect. To this end, we analyzed the
association of statins use with cardiovascular events in the
Hong Kong Diabetes Registry using various Cox models,
and compared the results against the known effect sizes of
statins on cardiovascular outcome from previous interven-
tional trials.
Validation of methods to control for immortal time bias
The benefit of statins in reducing cardiovascular disease
is well proven based on randomized controlled trials.
Using the Hong Kong Diabetes Registry, we compared
the effect of statins use on incident cardiovascular events
using the following statistical procedures: time-dependent
drug-exposure Cox models with adjustment for co-
variables at enrolment in non-users of statins and
time-dependent co-variables at the time of use of the
statins in users [15,16]; time-fixed Cox models with exclu-
sion of immortal time among statins users, with adjust-
ment for co-variables at enrolment in statins non-users
and co-variables in statins users [17], that is, moving the
start point of follow-up from enrolment to the end of
immortal time for statins users; and time-fixed Cox
model with inclusion of immortal time and adjustmentfor co-variables at enrolment for both users and non-users
of statins.
To obtain time-dependent values of co-variables, we
calculated partial regression coefficients of age (βa) and
duration of diabetes (βb) for demographic and metabolic
co-variables at enrolment in patients who were started
statins during follow-up. Next, we estimated the values
of BMI, systolic BP, HbA1c, LDL-C, HDL-C, triglyceride,
urine ACR and eGFR at the time of commencing statins,
using the following formula:
Xt ¼ Xb þ βaTi þ βbTi;
where Xt is the value at the time of starting statins dur-
ing follow-up, Xb is the value at baseline, and Ti is the
immortal time.
The validation showed that a time-fixed Cox model
with inclusion of immortal time, that is, ignoring im-
mortal time bias, produced a HR that was closest to the
values reported in literature (Additional file 1: Table S1).
The other models, particularly the time-dependent Cox
model, tended to inflate the HR, even after adjustment
for time-dependent co-variables and propensity score.
Our findings strongly supported the use of a time-fixed
Cox regression to estimate drug effects in our cohort. This
method was used in all our analyses of drug use with
cancer risk.
Results
At enrolment, the median age of the cohort was 57 years
(IQR: 47 to 67), duration of diabetes was 6 years (IQR: 2
to 11), and 46.1% were male (n = 2,808). Median follow-up
was 4.9 years (IQR: 2.8 to 7.0), with a mean of 4.8 ± 2.4
years, during which 271 patients (4.4%) developed cancer
with an incidence of 9.2 per 1,000 person-years (95% CI:
8.1, 10.3). Patients with incident cancers were older, more
likely to smoke cigarettes and drink alcohol, had longer
disease duration of diabetes, and had higher systolic BP
and urinary ACR but lower eGFR and triglyceride at base-
line than those without cancer. They were less likely to be
started on lipid-lowering agents including statins and
fibrates as well as oral blood glucose-lowering drugs in-
cluding metformin and TZDs during follow-up (Table 1).
Table 2 shows the HR of different drugs for cancer risk
after excluding prevalent users and adjusting for propensity
score (model 1); co-variables including LDL-C-related risk
indicators (that is, LDL-C <2.8 mmol/L plus albuminuria
or LDL-C ≥3.8 mmol/L), non-linear associations of HDL-C
and triglyceride with cancer, BMI (<24, ≥27.6 kg/m2),
HbA1c, age, sex, occupation, use of alcohol and tobacco,
disease duration of diabetes, and systolic BP; and drug use
during follow-up without (model 2) and with propensity
score for the drug in question (model 3).
Table 1 Clinical and biochemical characteristics and use of medications of the study cohort stratified by cancer status
Patients without cancer Patients with cancer
(n = 5,832) (n = 271)
Median (IQRa) or % (n) Median (IQRa) or % (n) P
Baseline variables
Age (years) 57 (20) 66 (15) <0.0001b
Male gender 45.8% (2,669) 51.3% (139) 0.0743c
Employment status <0.0001c
Full-time 33.1% (1,928) 17.7% (48)
Housewife 28.6% (1,665) 28.8% (78)
Retired 27.9% (1,628) 46.5% (126)
Others 10.5% (611) 7.0% (19)
Smoking status <0.0001c
Ex-smoker 15.10% (878) 18.7% (38)
Current smoker 14.8% (862) 23.2% (47)
Alcohol drinking status <0.0001c
Ex-drinker 11.8% (688) 21.0% (51)
Current drinker 7.3% (427) 7.4% (20)
Body mass index (kg/m2) 24.8 (4.9) 24.3 (4.7) 0.1296b
Duration of diabetes (years) 6 (9) 8 (10) 0.0202b
Glycated hemoglobin HbA1c (%) 7.2 (2.0) 7.4 (2.3) 0.3586b
Systolic BP (mmHg) 134 (27) 137 (25) 0.0011b
Diastolic BP (mmHg) 75 (14) 75 (16) 0.6152b
Glycated hemoglobin (%) 7.2 (2.0) 7.4 (2.3) 0.3586b
LDL-C (mmol/L) 3.10 (1.23) 3.10 (1.30) 0.8872b
HDL-C (mmol/L) 1.26 (0.43) 1.25 (0.51) 0.3846b
Triglyceride (mmol/L) 1.34 (1.02) 1.23 (0.77) 0.0014b
Total cholesterol (mmol/L) 5.10 (1.33) 5.00 (1.42) 0.3083b
ACR (mg/mmol) 2.06 (10.47) 3.45 (14.18) 0.0023b
eGFR (ml/min/1.73m2) 103.1 (41.6) 98.8 (37.3) 0.0184b
Prior myocardial infarction 2.0% (114) 2.6% (7) 0.4683d
Prior stroke 4.5% (261) 3.7% (10) 0.5396c
Death (all-cause) during follow-up 6.3% (369) 50.2% (163) <0.0001c
Use of medications 2.5 years prior to enrolment
Statins 15.5% (903) 10.3% (28) 0.0211c
Fibrates 4.5% (261) 3.3% (9) 0.3664c
ACEIs/ARBs 29.5% (1,718) 28.8% (78) 0.8114c
Insulin 23.9% (1,394) 25.8% (70) 4676c
Metformin 56.6% (3,303) 52.4% (142) 0.1691c
Sulphonylurea 62.4% (3,640) 63.5% (172) 0.7260c
TZDs 0.5% (28) 0.4% (1) 0.7949c
Use of medications during follow-upe
Statins 38.6% (2,249) 22.5% (61) <0.0001c
Fibrates 10.2% (595) 5.9% (16) 0.0212c
ACEIs/ARBs 57.9% (3,378) 52.4% (142) 0.0720c
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Table 1 Clinical and biochemical characteristics and use of medications of the study cohort stratified by cancer status
(Continued)
Insulin 37.7% (2197) 36.2% (98) 0.6161c
Metformin 74.5% (4,347) 63.8% (173) <0.0001c
Sulphonylurea 71.3% (4,160) 69.4% (188) 0.4864c
TZDs 6.8% (398) 0.7% (2) <0.0001c
ainterquartile range, IQR, for variables with skewed distribution; bderived from the Wilcoxon two-sample test; cderived from Chi-squared test; dderived from
the Fisher’s exact test; eincluding use started on or before enrolment but continued during follow-up period. ACEIs, angiotensin-converting enzyme
inhibitors; ACR, spot urine albumin-to-creatinine ratio; ARBs, angiotensin II receptor blockers; BP, blood pressure; eGFR, estimated glomerular filtration rate;
HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; RAS, renin-angiotensin system;
TZD, thiazolidinedione.
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sulphonylurea and TZD was independently associated
with a 40% to 60% risk reduction for all-site cancer.
Figure 2 shows the cumulative incidence of cancer in
patients stratified by the number of risk factors defined
as HbA1c ≥7% and non-use of statins and/or RAS in-
hibitors, as well as that by usage of individual drugs,
adjusted for all confounders. The numbers of patients
in different risk groups during the follow-up period
with reference to Figure 1 are shown in Additional file 1:
Table S2. Compared with patients with HbA1c < 7% who
started on statins and RAS inhibitors, those with high
HbA1c and treated with neither drug had a four-fold in-
creased risk of incident all-site cancer (incidence per 1,000
person-years (HR, (95% CI)): no risk factor, 3.40 (0.07,
6.72); one risk factor, 6.34 (4.19, 8.50); two risk factors,
8.40 (6.60, 10.20); three risk factors, 13.08 (9.82, 16.34);
P <0.001). We repeated the analyses by specific cancer
site but the number of cancers at specific sites was too
small to yield any significant results. Distribution of cancer
sites among the patients who developed cancers (n = 271)
and some patients had developed cancers at more than
one site were shown in table S3. (Additional file 1:
Table S3).Discussion
In this prospective cohort of Chinese patients with
type 2 diabetes without prior history of cancer or
exposure to the drugs in question, suboptimal glycemic
control (HbA1c ≥7%) and non-use of RAS inhibitors
and statins were associated with increased cancer risk
in an additive manner. While the incidence of cancer
was 9.21 per 1,000 person-years in the entire cohort,
non-users of RAS inhibitors and statins with HbA1c ≥7%
had four-fold higher incidence of cancer (13.08 per 1,000
person-years) than users of both drugs with HbA1c <7%
(3.40 per 1,000 person-years). Consistently, treatment with
insulin, metformin, sulphonylurea and TZD was associ-
ated with 40% to 80% reduced cancer risk after adjusting
for co-variables, drug indications, use of other drugs, and
lipid-associated risk factors for cancer.Effects of hyperglycemia on cancer risk
Warburg first reported in the 1920s that, under anaerobic
conditions, respiration due to fermentation (insufficient
oxygen) favored cancer cell growth over normal cell
growth, which is more dependent on aerobic respiration
(sufficient oxygen) [18]. Diabetes is a disorder of energy
metabolism caused by inadequate insulin action, either
quantitatively or qualitatively. The use of fat as an alter-
native energy substrate in diabetes promotes free fatty
acid production and oxidative stress. The latter can be
perpetuated by generalized vasculopathy with insufficient
oxygen and glucose delivery at a tissue level. Hypergly-
cemia can also activate cellular signals such as angiotensin
II, nicotinamide adenine dinucleotide phosphate oxidase,
aldose reductase, protein kinase C, advanced glycation
end products and nuclear factor kappa B, which interact
to cause abnormal cell cycles through oxidative stress and
inflammation [3,19]. Other researchers have reported the
proliferative effects of hyperglycemia on pancreatic cancer
cells [20] through dysregulation of multiple growth-
promoting pathways.
In support of these mechanistic studies, we [21] and
others [1] have reported the near-linear relationships of
fasting plasma glucose and HbA1c with cancer risk. For
every 1% increase in HbA1c, there is an 18% increase in
cancer risk in patients with type 2 diabetes [21]. Other
researchers have reported risk association between cancer
and fasting plasma glucose independent of obesity [22]
and between pancreatic cancer and 2-hour post-load
plasma glucose [23] in non-diabetic subjects. Similarly, pa-
tients with cancer in the highest tertile of fasting plasma
glucose have the lowest survival rate compared to those in
the lower tertiles [24].Drug usage and cancer risk
Despite the controversies regarding the use of insulin
and cancer risk, in a randomized clinical trial, the ORIGIN
(Outcomes Reduction with an Initial Glargine Intervention)
study, early treatment with insulin glargine in patients with
dysglycemia, including pre-diabetes and type 2 diabetes,
was not associated with increased cancer risk [25]. In this
Table 2 Hazard ratios of drug use for cancer in patients
with type 2 diabetes after excluding prevalent users for
the drug in question using a non-time-dependent Cox
regression model, with adjustment for co-variables,











Model 1 4,307 199 0.38 (0.27, 0.53) <0.00001
Model 2 4,307 199 0.60 (0.43, 0.84) 0.0027
Model 3 4,307 199 0.55 (0.39, 0.78) 0.0009
Statins
Model 1 5,172 243 0.36 (0.24, 0.53) <0.0001
Model 2 5,172 243 0.47 (0.32, 0.70) 0.0002
Model 3 5,172 243 0.47 (0.31, 0.70) 0.0003
Insulin
Model 1 4,639 201 0.48 (0.31, 0.73) 0.0006
Model 2 4,639 201 0.59 (0.39, 0.89) 0.0110
Model 3 4,639 201 0.58 (0.38, 0.89) 0.0119
Metformin
Model 1 2,658 129 0.38 (0.25, 0.56) <0.0001
Model 2 2,658 129 0.39 (0.25, 0.61) <0.0001
Model 3 2,658 129 0.39 (0.25, 0.61) <0.0001
Sulphonylurea
Model 1 2,291 99 0.45 (0.29, 0.72) 0.0008
Model 2 2,291 99 0.44 (0.27, 0.73) 0.0013
Model 3 2,291 99 0.44 (0.27, 0.73) 0.0014
TZDs
Model 1 6,074 270 0.12 (0.03, 0.50) 0.0033
Model 2 6,074 270 0.17 (0.04, 0.69) 0.0133
Model 3 6,074 270 0.18 (0.04, 0.72) 0.0153
Model 1 adjusted for propensity scores (c-statistics = 0.80 for ACEIs or ARBs;
0.80 for statins; 0.79 for insulin; 0.73 for metformin; 0.66 for sulphonylurea;
and 0.74 for TZDs), which were calculated using logistic regression procedures
with age, sex, body mass index, low- and high-density lipoprotein cholesterols
(LDL-C and HDL-C), triglyceride, use of tobacco and alcohol, HbA1c, systolic
blood pressure, natural log of the albumin-to-creatinine ratio, estimated
glomerular filtration rate, duration of disease, peripheral arterial disease,
retinopathy, neuropathy, prior myocardial infarction and stroke as independent
variables. Model 2 adjusted for LDL-C-related risk indicators (that is, LDL-C <2.8
mmol/L plus albuminuria or LDL-C ≥3.8 mmol/L); non-linear associations of HDL-C
and triglyceride for cancer; body mass index (<24, ≥27.6 kg/m2); age; sex;
employment status; use of tobacco and alcohol; duration of disease; systolic
blood pressure; and use of statins, ACEIs/ARBs, fibrates, sulphonylurea, metformin
and TZDs during follow-up. Model 3 adjusted for all factors in model 2 plus the
propensity score of the drug in question. No patient had been exposed to the drug
in question for at least 2.5 years prior to enrolment. ACEIs, angiotensin-converting
enzyme inhibitors; ARBs, angiotensin II receptor blockers; CI, confidence interval;
TZD, thiazolidinediones.
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person-years, similar to that of 0.92 per 100 person-years
in the present report. In a previous analysis using validated
methods (that is, a sensitivity analysis with use of the time-
fixed Cox model), insulin users had a 51% risk reduction incancer risk compared with non-users, probably due to insu-
lin’s effects on blood glucose lowering [21].
Both diabetes and cancer are complex diseases due to
multi-causality [26]. There are many reasons for the in-
consistent, and sometimes conflicting, results regarding
the risk associations of cancer with drugs from studies
that were often not designed to address the question in
the first place. These include heterogeneity of study popu-
lations, quality of data collection, inclusion and exclusion
of various confounders, and study design and setting.
Recently, we summarized potential biases in pharma-
coepidemiological analysis including lack of adjustment
for confounders and drug indication (for example, using
the propensity score), inclusion of prevalent drug users,
adjustment for immortal time and use of time-dependent
analysis [27]. In our present validation of various statistical
methods on estimating drug effects, we demonstrated that
different conclusions can be drawn regarding the risk and
benefit of statins on cardiovascular diseases using the
same database. Not to disregard the theoretical possibility
of immortal time bias, our results clearly suggest that
attempts to remove immortal time using alternative
methods such as time-dependent Cox regression were
prone to biases from other sources, as evidenced by the
generation of HRs that were severely inflated. Conversely,
the use of conservative time-fixed Cox regression with in-
clusion of immortal time produced an effect size most
comparable to that obtained in major interventional trials,
suggesting that immortal time may have only limited im-
pact in pharmacoepidemiological analysis.
Insulin deficiency versus insulin resistance
Hyperglycemia can dysregulate intracellular signaling
pathways and may impact on cancer cell growth [3,5].
Both insulin deficiency and resistance can contribute to
hyperglycemia, which can vary between individuals and
within the same individual over time. Chronic hyperinsuli-
nemia increases risk of cancers of the colon, endometrium
and probably other sites, including pancreas and kidneys
[28]. Using chemically induced hepatocarcinogenesis
in diabetic model mice genetically deficient for insulin,
volumes of hepatocellular tumors were more than two-
fold larger in the insulin-deficient mice compared with
the normal controls, suggesting that insulin-independent
mechanisms might operate in liver tumor growth [29].
As such, we and others have also reported the atten-
uated cancer risk associated with metformin or TZD
treatment. Both ApoA-1 and metformin interact with
tumor-suppressive liver kinase B1 to activate adenosine
monophosphate-activated protein kinase. In this context,
metformin-treated type 2 diabetic patients with low HDL-C
had markedly attenuated cancer risk than non-users, sug-
gesting possible drug-sub-phenotype interaction. In another
sub-analysis, we reported 80% risk reduction in cancer
Figure 2 Cumulative incidence of all-site cancer in patients with type 2 diabetes. Stratified by drug usage and attainment of glycemic goal
after adjustment for LDL-C-related risk indicators (that is, LDL-C < 2.8 mmol/L plus albuminuria or LDL-C ≥3.8 mmol/L), non-linear associations of
HDL-C and triglyceride with cancer, BMI (<24, ≥27.6 kg/m2), HbA1c, (except for Figure 1a) age, sex, employment status, use of alcohol and tobacco,
duration of disease, and systolic blood pressure. Additional adjustments were made for propensity scores of the drug in question and use of other
medications during follow-up as appropriate. All analyses were performed after excluding prevalent drug users. Abbreviation list: LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index; HbA1c, glycated haemoglobin; RAS, renin-angiotensin
system; TZD, thiazolidinedione.
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probably due to TZD’s ameliorating effects on gluco-
lipotoxicity, inflammation and oxidative stress through
fat redistribution [2]. In a national database from Taiwan,
patients with diabetes treated with any anti-diabetic drugs
had 10% to 60% lower risk of liver cancer than non-users,with metformin and TZD having the largest effect size
[30]. In a prospective cohort of patients with breast can-
cers, users of TZD and metformin had better survival
rates than non-users, with both drugs conferring 50% risk
reduction in mortality [31]. In a recent meta-analysis, the
risk association of TZD with bladder cancer appeared to
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rather than class effect [32].
Inhibition of HMGCR and RAS pathways on cancer risk
Although there are strong experimental and clinical data
supporting the anti-cancer effects of statins [33], the
situation is more controversial with respect to RAS inhibi-
tors. In response to a report on risk association of cancer
with RAS inhibitors, we used data from our registry to
point out the independent risk association of cancer with
propensity score for RAS inhibitors. Our findings suggest
that microenvironments associated with RAS activation
linked to hyperglycemia, high BP and renal dysfunction
might promote cancer growth in predisposed subjects [4].
Herein, experimental studies suggest intimate relation-
ships between insulin, sterol regulatory element-binding
proteins (SREBPs), insulin-like growth factor-1 (IGF1) and
3-hydroxy-3-methyl-glutaryl-coenzyme-A-reductase
(HMGCR) pathways (Figure 2). Insulin regulates triglycer-
ide synthesis through activation of the SREBP-1c pathway
while IGF1 activates the SREBP-1a pathway to promote
cholesterol synthesis via the HMGCR pathway. However,
the latter can lead to increased production of mevalonate
and Ras signals, which are known oncogenes. Since
both insulin and IGF1 pathways share cognate receptors,
insufficient insulin action may cause dysregulation of the
IGF1-SREBP-HMGCR-mevalonate-Ras pathway to increase
cancer risk [2]. In a uninephrectomized rat model charac-
terized by sequential development of dysglycemia, renal
dysfunction and renal cancer, we found activation of the
RAS pathway, reduced expression of IGF-binding proteins
and increased expression of HMGCR, protein kinase C
ξ and Akt (or protein kinase B) which were reversed by
treatment with RAS inhibitors, with reduced cancer
growth, suggesting crosstalk between the RAS and
HMGCR pathways [34].
Strengths and weaknesses
Despite the limitations of observational studies and
pharmacoepidemiological analysis, there is now a grow-
ing body of clinical and experimental data that support
the cancer-promoting effects of hyperglycemia and, import-
antly, the potentially preventable nature of cancer. In this
article, we have used detailed analysis with corroborative
evidence from independent studies to argue for the possible
causal role of hyperglycemia and associated changes in
microenvironment in promoting cancer growth using the
criteria set out by Bradford-Hill [35]. The latter include
strength of associations (cancer risk and diabetes with
odds ratio ≥1.3 to 3) [1], specificity (cancer risk attenuated
only by adjusting blood glucose) [1], temporal relationship
(prospective cohorts and association of cancer risk in
pre-diabetes) [22,36], biological gradient (linear relation-
ship of cancer risk with HbA1c and plasma glucose) [1,21],biological plausibility (activation of multiple and interlinked
pathways by hyperglycemia) [3], coherence (high prevalence
of diabetes in cancer and improved cancer survival in
patients treated with blood glucose lowering drugs), ex-
periments [29] and analogy (growth-promoting effects
of hyperglycemia in renal and endothelial cells) [37]. Of
note, socioeconomic status such as educational attainment,
income, employment and occupation might lead to prefer-
ential prescription of certain drugs, which might potentially
lead to allocation bias. In this regard, we had adjusted for
employment status and the difference before and after the
adjustment had little impacts on the effect sizes of drug
use reported in this study. Since Hong Kong has a heavily
subsidized healthcare system and all patients only have to
pay a nominal fee of less than 2 US dollars per drug item
lasting for 3 to 4 months with waiving of all fees if they
are on social security, socioeconomic status or education
level were not likely to be important factors in drug selec-
tion in the present cohort. We were not sure about the ef-
fects of these socioeconomic factors on drug compliance
but this was likely to be random and equally distributed in
both groups. That said, due to the public nature of the
hospital, there might be an under-representation of
patients from the younger population and upper socio-
economic class who might seek additional anti-cancer
treatment in the private sector. Due to the low numbers
of cancers at specific sites, we could not explore the asso-
ciations between diabetes and site-specific cancer.
Taken together, the systematic and comprehensive
documentation of baseline risk factors, long duration
of follow-up, concurrent drug use, and clinical outcomes
are the major strengths of this cohort. We cannot exclude
inclusion of subclinical cases of cancer, although only
39.1% (n = 106) of cancer cases occurred within the first 2
years of enrolment. We cannot exclude other unmeasured
variables (for example, better treatment compliance,
lifestyle factors, quality of care) associated with better
glycemic control and use of these drugs, which might
confound these associations. Despite adjustment for
propensity score, potential confounding by indication
remains.
Conclusion
Despite the proven benefits of control of multiple risk
factors in type 2 diabetes, in real practice, glycemic control
is often suboptimal with omission of many life-saving
drugs. In developing areas such as Asia where beta cell
insufficiency, metabolic syndrome, low grade chronic
infections (for example, hepatitis B), early onset of dis-
ease and renal dysfunction characterized by oxidative
stress and microinflammation are highly prevalent [6],
our findings carry important public and personal health im-
plications. In this light, Asians living in the US had higher
rates of gastric cancer than their white counterparts [38].
Kong et al. BMC Medicine 2014, 12:76 Page 10 of 11
http://www.biomedcentral.com/1741-7015/12/76Against this background, our findings suggest that use of
RAS inhibitors and statins may prevent the adverse conse-
quences of abnormal microenvironment in diabetes that
may promote loss of functions or abnormal cell growth.
While well-designed prospective cohorts, randomized tri-
als and mechanistic studies are needed to confirm our
findings, given the complex yet probabilistic nature of the
effects on host-environment-lifestyle interactions on
clinical outcomes, our data also highlight the opportun-
ities for preventing multiple morbidities in diabetes by
strengthening our healthcare system to optimize risk
factor control and promote patient empowerment with
ongoing monitoring and evaluation [39].
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